Cisplatin (Adverse Reactions)

Cisplatin is an alkylating agent widely used in chemotherapy against different types of cancer in both children and adults. The TPMT enzyme is involved in its metabolism, so polymorphisms in this gene are associated with adverse treatment reactions such as hearing loss.

Cisplatin, or cis-diamminedichloroplatinum(II), is a well-known metal-based chemotherapeutic drug used in the standard treatment of various solid cancers such as testicular, breast, ovarian, head and neck, bladder, lung, cervical, stomach, melanoma, neuroblastoma, osteosarcoma, and lymphomas. Depending on the type of cancer, cisplatin can be used alone or with other compounds such as, for example, paclitaxel, in the treatment of ovarian cancer.

Two of the main limitations of cisplatin use are treatment resistance and toxicity. Multiple platinum compounds have been produced to minimize the development of treatment resistance and improve pharmacokinetic properties. Some of the platinum compounds alternative to cisplatin are carboplatin, oxaliplatin, satraplatin, and nedaplatin.

The main toxicities derived from cisplatin treatment are nephrotoxicity, ototoxicity, hepatotoxicity, gastrointestinal toxicity, and neurotoxicity.

MECHANISM OF ACTION

The main mechanism through which cisplatin exerts its action is the interaction with genomic and mitochondrial DNA and the generation of damage in its structure, activating apoptosis (cell death).

CONTRAINDICATIONS

Cisplatin should be avoided in patients with hypersensitivity to cisplatin or other platinum-based compounds, renal dysfunction, dehydration, myelosuppression, hearing impairment, or neuropathy caused by cisplatin.

SIDE EFFECTS

Cisplatin is a medication that can cause toxicity and multiple adverse effects including: infections, sepsis, hematological disorders (leukopenia, thrombocytopenia, and anemia), low blood sodium levels, venous thromboembolism, peripheral neuropathy, hearing loss, vertigo, cardiac arrhythmia, erythema, skin ulcer, and localized edema.

Cisplatin ototoxicity is one of the most frequent adverse reactions, manifesting as permanent bilateral hearing loss, affecting 10-25% of adults and 26-90% of children.

TRADE NAMES

  • Platinol®
  • Platinol-AQ®

Genes analyzed

TPMT

Bibliography

Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019 Jul;88:102925.

Lee JW, Pussegoda K, Rassekh SR, et al. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. Ther Drug Monit. 2016 Aug;38(4):423-31.

Thiesen S, Yin P, Jorgensen AL, et al. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenet Genomics. 2017 Jun;27(6):213-222.

What do your genes say about you? Start your journey today.

Get a special 5% discount on your first kit.

Haven't you taken our DNA test yet?

Get your genetic test and discover what your DNA says about you.

pack
Starter DNA test
The best option to get started

Ancestry service, Traits and Wellness

Buy
pack
DNA test Advanced DNA test
Know your DNA in depth

Health, Ancestry service, Traits and Wellness

Buy
pack
Genetic analysisUltra
Whole Genome Sequencing 30x

Health, Ancestrality, Traits and Wellness

includes three months of tellmeGen+

Buy

Important information and limitations

Europe
Austria
Belgium
Czech Republic
Denmark
Finland
Germany
Hungary
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Romania
Spain
Sweden
Switzerland
United Kingdom
Asia
Kazakhstan
Saudi Arabia
UAE
America
Brazil
Canada
Chile
Colombia
Mexico
Panama
Peru
United States
Oceania
Australia
The Best Prices of the Year! Only until November 27 Use our coupon BLACK15
Buy